[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629422":3},{"organization":4,"armGroups":7,"interventions":32,"overallOfficials":41,"centralContacts":46,"locations":52,"responsibleParty":62,"collaborators":37,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":37,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":72,"minAge":73,"maxAge":37,"enrollmentInfo":74,"targetDuration":37,"studyType":77,"phases":78,"briefSummary":81,"conditions":82,"keywords":37,"overallStatus":84,"whyStopped":37,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"CellinCells","INDUSTRY",[8,14,18,24,28],{"label":9,"type":10,"description":11,"interventionNames":12},"TRTP-101","EXPERIMENTAL","High-dose TRTP-101",[13],"Biological: TRTP-101",{"label":15,"type":10,"description":16,"interventionNames":17},"TRPT-101 (Low dose group)","In a split-face design, low-dose TRTP-101 is administered to one side of the face and placebo to the contralateral side.",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Placebo (Low dose group)","PLACEBO_COMPARATOR","In a split-face design, placebo is administered to one side of the face and low-dose TRTP-101 to the contralateral side.",[23],"Biological: Placebo",{"label":25,"type":10,"description":26,"interventionNames":27},"TRPT-101 (High dose group)","In a split-face design, high-dose TRTP-101 is administered to one side of the face and placebo to the contralateral side.",[13],{"label":29,"type":20,"description":30,"interventionNames":31},"Placebo (High dose group)","In a split-face design, placebo is administered to one side of the face and high-dose TRTP-101 to the contralateral side.",[23],[33,38],{"type":34,"name":9,"description":35,"armGroupLabels":36,"otherNames":37},"BIOLOGICAL","Intradermal injection",[25,15,9],null,{"type":34,"name":39,"description":35,"armGroupLabels":40,"otherNames":37},"Placebo",[29,19],[42],{"name":43,"affiliation":44,"role":45},"Jonghee Lee, MD","Samsung Medical Center","PRINCIPAL_INVESTIGATOR",[47],{"name":48,"role":49,"phone":50,"phoneExt":37,"email":51},"HyeJung Park","CONTACT","+82-70-4469-9115","hjpark@cellincells.com",[53],{"facility":44,"status":37,"city":54,"state":37,"zip":37,"country":55,"countryCode":37,"cosmosGeoPoint":56,"geoPoint":61,"contacts":37},"Seoul","South Korea",{"type":57,"coordinates":58},"Point",[59,60],126.9784,37.566,{"lat":60,"lon":59},{"type":63,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR","100629422","phase-1-safety-and-efficacy-of-autologous-adipose-derived-mesenchymal-stem-cells-therapy-in-adults-with-atrophic-scars-100629422",false,"NCT07474467","Safety and Efficacy of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Split-Face, Phase 1\u002F2 Study to Evaluate the Safety and Efficacy of a Single Administration of TRTP-101 in Adults With Atrophic Scars","Inclusion Criteria:\n\n* Male or Female aged greater than 19 years\n* Acne scars graded ≥ 3 on the 5-point ASRS\n\n\\[Phase 1\\]\n\n* Four or more atrophic scars in the joints, genitals, perineum, and face except for the lips, eyes and nose\n\n\\[Phase 2\\]\n\n* Atrophic scar lesions approximately 2 cm in diameter located on the cheeks or temple on both sides of the face\n* A response of \"dissatisfied\" or worse on the Subject Acne Scar Self-Assessment Scale\n\nExclusion Criteria:\n\n* History of cell therapy\n* Treatment of Dermal resurfacing, Chemical\u002FMechanical Peel and Skin Photorejuvenation\n* Treatment of Hyaluronic acid\u002Fcollagen skin filler, non-permanent soft tissue filler and fat grafting\n* Positive for virus infection\n* Use of Anticoagulant therapy or NSAIDs\n* Thrombocytopenia or other coagulation disorder\n* History of keloid scars\n* Infectious disease or other dermatitis in the area of the atrophic scar\n* Use of Immunosuppressant, immunomodulating drug, anticancer drug or radiation therapy\n* Use of systemic steroid medication\n* History of hypersensitivity or severe allergic reactions (e.g., anaphylaxis, Guillain-Barre syndrome, etc.)\n* Use of retinoid medications",true,"ALL","19 Years",{"count":75,"type":76},31,"ESTIMATED","INTERVENTIONAL",[79,80],"PHASE1","PHASE2","The purpose of this clinical trial was to evaluate the safety and efficacy of a single administration of TRTP-101 in adults with atrophic scars.",[83],"Atrophic Scar","NOT_YET_RECRUITING","2026-03-11",{"date":87,"type":88},"2026-03-16","ACTUAL",{"date":90,"type":76},"2026-08-01",{"date":92,"type":76},"2029-08-01",{"name":5,"class":6},1]